# Nikhil C. Munshi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nikhil-c-munshi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 97,729 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 152 |
| i10-index | 627 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5045740077 |
| ORCID iD | 0000-0002-7344-9795 |
| Works | 1,582 |

## Researcher papers

Showing 12 of 22.

- [Signatures of mutational processes in human cancer](https://scholariq.org/papers/signatures-of-mutational-processes-in-human-cancer/)
- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Antitumor Activity of Thalidomide in Refractory Multiple Myeloma](https://scholariq.org/papers/antitumor-activity-of-thalidomide-in-refractory-multiple-myeloma/)
- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells](https://scholariq.org/papers/lenalidomide-causes-selective-degradation-of-ikzf1-and-ikzf3-in-multiple-myeloma/)
- [Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/anti-bcma-car-t-cell-therapy-bb2121-in-relapsed-or-refractory-multiple-myeloma/)
- [Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer](https://scholariq.org/papers/nephrectomy-followed-by-interferon-alfa-2b-compared-with-interferon-alfa-2b/)
- [Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study](https://scholariq.org/papers/ciltacabtagene-autoleucel-a-b-cell-maturation-antigen-directed-chimeric-antigen/)
- [Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-with-transplantation-for-myeloma/)
- [Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts](https://scholariq.org/papers/somatic-i-sf3b1-i-mutation-in-myelodysplasia-with-ring-sideroblasts/)
- [Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-combination-therapy-in-patients-with/)
- [A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma](https://scholariq.org/papers/a-randomized-phase-2-study-of-lenalidomide-therapy-for-patients-with-relapsed-or/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.